ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2011
Progress in the rational design of an AIDS vaccine.
Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Trial
- Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients.PLoS pathogens · 2012Trial
- Cohort-Specific Peptide Reagents Broaden Depth and Breadth Estimates of the CD8 T Cell Response to HIV-1 Gag Potential T Cell Epitopes.Vaccines · 2023Article
- Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.Nature communications · 2022Article
- Comprehensive epitope mapping using polyclonally expanded human CD8 T cells and a two-step ELISpot assay for testing large peptide libraries.Journal of immunological methods · 2021Article
- Targeting the N332-supersite of the HIV-1 envelope for vaccine design.Expert opinion on therapeutic targets · 2020Review
- Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer.Nature communications · 2018Article
- Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.Frontiers in immunology · 2017Article
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.International journal of molecular sciences · 2016Review
- Recent Insights into the HIV/AIDS Pandemic.Microbial cell (Graz, Austria) · 2016Review
- Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?AIMS public health · 2015Review
- Editorial: Paradigm Changes are Required in HIV Vaccine Research.Frontiers in immunology · 2015Article
- Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Virology · 2014Article
- Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.Cell reports · 2014Article
- Article
- An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Frontiers in immunology · 2014Review
- Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake up Call.Journal of AIDS & clinical research · 2013Article
- Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.Journal of virology · 2013Article
- Catching HIV 'in the act' with 3D electron microscopy.Trends in microbiology · 2013Review
- Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Human immunodeficiency virus-1 (HIV-1) has a high degree of genetic and antigenic diversity that has impeded the development of an effective vaccine using traditional methods. We are attempting to develop an AIDS vaccine by employing strategies that include structural biology and computational modelling, in an effort to develop immunogens capable of eliciting neutralizing antibodies of the requisite breadth and potency against circulating strains of HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.